KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 3

Serum S100B, NSE, and GRIA1 levels as neurological biomarkers in lead exposure

Ömer Hınç YILMAZ
Engin TUTKUN
Müjgan ERCAN
Sevilay SEZER
Esra FIRAT OĞUZ
Fatma Meriç YILMAZ
Sayfa
449–454
Yayın Tarihi
2022-11-04
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

GRIA1 levels might be used as a biomarkerfor the neurotoxicity of lead.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: The central nervous system is one of the major targets in lead exposure.
📊
Temel Bulgular & Veri:In this study, serum S100B, neuron-specific enolase (NSE), and glutamate receptor 1 (GRIA1)levels were determined as possible biomarkers for lead neurotoxicity.Material and methods: Twenty-five subjects with chronic lead exposure and 25 controls were included in the study.
💡
Sonuç & Katkı:GRIA1 levels might be used as a biomarkerfor the neurotoxicity of lead.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: The central nervous system is one of the major targets in lead exposure. Biomarkers for the diagnosis and follow-upof lead exposure have not been identified. In this study, serum S100B, neuron-specific enolase (NSE), and glutamate receptor 1 (GRIA1)levels were determined as possible biomarkers for lead neurotoxicity.Material and methods: Twenty-five subjects with chronic lead exposure and 25 controls were included in the study. NSE and S100Bwere measured by electrochemiluminescence immunoassay with a Cobas E601 analyzer. GRIA1 levels were measured with an ELISAkit using a quantitative sandwich enzyme immunoassay technique.Results: GRIA1 levels were significantly higher in the lead exposure group than in the control group. No significant differences for NSE,S100B, ALT, AST, or creatinine in sera were found between lead exposure and control groups.Conclusion: Subjects with chronic lead exposure are found to have increased glutamate receptor levels and do not seem to have glial orneuronal damage, which can be demonstrated with the elevation of NSE and S100B levels. GRIA1 levels might be used as a biomarkerfor the neurotoxicity of lead.

🔖

Bu Makaleye Atıf Yap

YILMAZ, Ö. H., TUTKUN, E., ERCAN, M., SEZER, S., OĞUZ, E. F., YILMAZ, F. M. (2022). Serum S100B, NSE, and GRIA1 levels as neurological biomarkers in lead exposure. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 3, 449–454. https://ajindex.com/articles/610263

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Gillis BS, Arbieva Z, Gavin IM. Analysis of lead toxicity in human cells. BMC Genomics 2012; 13: 344. Flora G, Gupta D, Tiwari A. Toxicity of lead: a review with recent updates. Interdiscip Toxicol 2012; 5: 47-58.
  2. Verstraeten SV, Aimo L, Oteiza PI. Aluminium and lead: molecular mechanisms of brain toxicity. Arch Toxicol 2008; 82: 789-802.
  3. Sanders T, Liu Y, Buchner V, Tchounwou PB. Neurotoxic effects and biomarkers of lead exposure: a review. Rev Environ Health 2009; 24: 15-45.
  4. Shukla PK, Khanna VK, Khan MY, Srimal RC. Protective effect of curcumin against lead neurotoxicity in rat. Hum Exp Toxicol 2003; 22: 653-658.
  5. Raunio S, Tahti H. Glutamate and calcium uptake in astrocytes after acute lead exposure. Chemosphere 2001; 44: 355-359.
  6. Giacoppo S, Bramanti P, Barresi M, Celi D, Foti Cuzzola V, Palella E, Marino S. Predictive biomarkers of recovery in traumatic brain injury. Neurocrit Care 2012; 16: 470-477. van Munster BC, Korse CM, de Rooij SE, Bonfrer JM, Zwinderman AH, Korevaar JC. Markers of cerebral damage during delirium in elderly patients with hip fracture. BMC Neurol 2009; 9: 21. Santiago AR, Gaspar JM, Baptista FI, Cristovao AJ, Santos PF, Kamphuis W, Ambrosio AF. Diabetes changes the levels of ionotropic glutamate receptors in the rat retina. Mol Vis 2009; 15: 1620-1630.
  7. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999; 51: 7-61.
  8. Nihei MK, Guilarte TR. Molecular changes in glutamatergic synapses induced by Pb2+: association with deficits of LTP and spatial learning. Neurotoxicology 2001; 22: 635-643.
  9. Bressler J, Kim KA, Chakraborti T, Goldstein G. Molecular mechanisms of lead neurotoxicity. Neurochem Res 1999; 24: 595-600.
  10. Xu J, Yan HC, Yang B, Tong LS, Zou YX, Tian Y. Effects of lead exposure on hippocampal metabotropic glutamate receptor subtype 3 and 7 in developmental rats. Journal of Negative Results in Biomedicine. 2009; 8: 1-8. Petroff OA. GABA and glutamate in the human brain. Neuroscientist 2002; 8: 562-573.
  11. Yilmaz FM, Yilmaz H, Tutkun E, Uysal S, Carman KB, Dilber C, Ercan M. Serum biochemical markers of central nerve system damage in children with acute elemental mercury intoxication. Clin Toxicol (Phila) 2014; 52: 32-38.
  12. Schreiber SS, Baudry M. Selective neuronal vulnerability in the hippocampus--a role for gene expression? Trends Neurosci 1995; 18: 446-451.
  13. Nava-Ruiz C, Mendez-Armenta M, Rios C. Lead neurotoxicity: effects on brain nitric oxide synthase. J Mol Histol 2012; 43: 553-